Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
The Commissioner’s National Priority Voucher pilot program enabled rolling review, enhanced FDA interaction, and a rapid 44-day decision, alongside breakthrough therapy and priority review ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment. A study supported by ...
The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.
Yesterday, the U.S. Food and Drug Administration approved the first blood-based genetic test that can detect gene mutations in non-small cell lung cancer patients. The cobas EGFR Mutation Test v2 is a ...
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Higher drug exposure in women due to lower renal and hepatic clearance and body composition can increase efficacy but also toxicity, highlighting the need to reassess dosing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results